
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8598970/publications.pdf Version: 2024-02-01



Δίρο Μληζιή

#	Article	IF	CITATIONS
1	Nasopharyngeal virome analysis of COVIDâ€19 patients during three different waves in Campania region of Italy. Journal of Medical Virology, 2022, , .	2.5	9
2	Human Enterovirus B: Selective Inhibition by Quinoxaline Derivatives and Bioinformatic RNA-Motif Identification as New Targets. Pharmaceuticals, 2022, 15, 181.	1.7	2
3	Neutralizing Antibodies Responses against SARS-CoV-2 in a Sardinian Cohort Group Up to 9 Months after BNT162b2 Vaccination. Vaccines, 2022, 10, 531.	2.1	5
4	Gut Microbiota Markers and Dietary Habits Associated with Extreme Longevity in Healthy Sardinian Centenarians. Nutrients, 2022, 14, 2436.	1.7	18
5	Evaluation of humoral and cellular response to third dose of BNT162b2 mRNA COVID-19 vaccine in patients treated with B-cell depleting therapy. Journal of Autoimmunity, 2022, 131, 102848.	3.0	10
6	Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopaâ€carbidopa intrajejunal gel. European Journal of Neurology, 2021, 28, 1198-1209.	1.7	20
7	Clinical Phenotypes of Parkinson's Disease Associate with Distinct Gut Microbiota and Metabolome Enterotypes. Biomolecules, 2021, 11, 144.	1.8	33
8	Gut microbiota markers associated with obesity and overweight in Italian adults. Scientific Reports, 2021, 11, 5532.	1.6	169
9	Bovine Viral Diarrhea Virus (BVDV): A Preliminary Study on Antiviral Properties of Some Aromatic and Medicinal Plants. Pathogens, 2021, 10, 403.	1.2	8
10	Diet-Derived Antioxidants and Their Role in Inflammation, Obesity and Gut Microbiota Modulation. Antioxidants, 2021, 10, 708.	2.2	47
11	Antiviral Activity of Vitis vinifera Leaf Extract against SARS-CoV-2 and HSV-1. Viruses, 2021, 13, 1263.	1.5	53
12	Parkinson's Disease: A Prionopathy?. International Journal of Molecular Sciences, 2021, 22, 8022.	1.8	12
13	SARS-CoV-2 and Its Variants: The Pandemic of Unvaccinated. Frontiers in Microbiology, 2021, 12, 749634.	1.5	3
14	Metabolic Alteration in Plasma and Biopsies From Patients With IBD. Inflammatory Bowel Diseases, 2021, 27, 1335-1345.	0.9	10
15	Genetic variants of TAS2R38 bitter taste receptor associate with distinct gut microbiota traits in Parkinson's disease: A pilot study. International Journal of Biological Macromolecules, 2020, 165, 665-674.	3.6	23
16	Gut Microbiota and Metabolome Alterations Associated with Parkinsonâ \in Ms Disease. MSystems, 2020, 5, .	1.7	161
17	Impact of a Moderately Hypocaloric Mediterranean Diet on the Gut Microbiota Composition of Italian Obese Patients. Nutrients, 2020, 12, 2707.	1.7	33
18	Metabolomic profile of systemic sclerosis patients. Scientific Reports, 2018, 8, 7626.	1.6	30

#	Article	IF	CITATIONS
19	Cross sectional evaluation of the gut-microbiome metabolome axis in an Italian cohort of IBD patients. Scientific Reports, 2017, 7, 9523.	1.6	298
20	1H NMR spectroscopy-based metabolomics analysis for the diagnosis of symptomatic E. coli-associated urinary tract infection (UTI). BMC Microbiology, 2017, 17, 201.	1.3	22
21	Cyclovirus Vietnam DNA in immunodeficient patients. Journal of Clinical Virology, 2016, 81, 12-15.	1.6	6
22	Lack of usutu virus RNA in cerebrospinal fluid of patients with encephalitis of unknown etiology, Tuscany, Italy. Journal of Medical Virology, 2015, 87, 913-916.	2.5	4
23	Global impact of Torque teno virus infection in wild and domesticated animals. Journal of Infection in Developing Countries, 2015, 9, 562-570.	0.5	30
24	High Prevalence of Co-Infection with Multiple Torque Teno Sus Virus Species in Italian Pig Herds. PLoS ONE, 2014, 9, e113720.	1.1	15
25	Usefulness of capillary electrophoresis-based multiplex PCR assay for species-specific identification of Candida spp Journal of Microbiological Methods, 2013, 92, 150-152.	0.7	5
26	Human Arthropod-Borne Viral Infections. BioMed Research International, 2013, 2013, 1-2.	0.9	3
27	Role of PCR in Helicobacter pylori diagnostics and research – new approaches for study of coccoid and spiral forms of the bacteria. Postepy Higieny I Medycyny Doswiadczalnej, 2013, 67, 261-268.	0.1	20
28	Molecular analysis of hepatitis B virus (HBV) in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy. BMC Infectious Diseases, 2011, 11, 310.	1.3	21
29	Genetic diversity of Streptococcus suis clinical isolates from pigs and humans in Italy (2003-2007). Eurosurveillance, 2009, 14, .	3.9	60
30	Active hepatitis C virus infection in bone marrow and peripheral blood mononuclear cells from patients with mixed cryoglobulinaemia. Clinical and Experimental Immunology, 2008, 97, 87-93.	1.1	89
31	<i>Streptococcus suis</i> Meningitis without History of Animal Contact, Italy. Emerging Infectious Diseases, 2008, 14, 1946-1949.	2.0	48
32	Composite Structure of <i>Streptococcus pneumoniae</i> Containing the Erythromycin Efflux Resistance Gene <i>mef</i> (I) and the Chloramphenicol Resistance Gene <i>catQ</i> . Antimicrobial Agents and Chemotherapy, 2007, 51, 3983-3987.	1.4	45
33	New Tn916-related elements causing erm(B)-mediated erythromycin resistance in tetracycline-susceptible pneumococci. Journal of Antimicrobial Chemotherapy, 2007, 60, 127-131.	1.3	71
34	Unusual Clinical Presentation of Mycobacterium fortuitum Infection in an Immunocompetent Woman. Journal of Clinical Microbiology, 2007, 45, 1663-1665.	1.8	21
35	Transmission in vitro of hepatitis C virus from persistently infected human B-cells to hepatoma cells by cell-to-cell contact. Journal of Medical Virology, 2006, 78, 192-201.	2.5	30
36	Prophage association of mef(A) elements encoding efflux-mediated erythromycin resistance in Streptococcus pyogenes. Journal of Antimicrobial Chemotherapy, 2005, 55, 445-451.	1.3	40

#	Article	IF	CITATIONS
37	Molecular Characterization of Pneumococci with Efflux-Mediated Erythromycin Resistance and Identification of a Novel mef Gene Subclass, mef (I). Antimicrobial Agents and Chemotherapy, 2005, 49, 4999-5006.	1.4	50
38	Molecular Characterization of Clinical Streptococcus pneumoniae Isolates with Reduced Susceptibility to Fluoroquinolones Emerging in Italy. Microbial Drug Resistance, 2004, 10, 209-217.	0.9	18
39	Molecular Characterization of Clinical <i>Streptococcus pneumoniae</i> Isolates with Reduced Susceptibility to Fluoroquinolones Emerging in Italy. Microbial Drug Resistance, 2004, 10, 209-217.	0.9	0
40	Acute myocarditis associated with adenoviral infection in a patient with scleroderma. Clinical Rheumatology, 2003, 22, 487-490.	1.0	10
41	Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. Journal of Hepatology, 2001, 34, 748-755.	1.8	75
42	Lamivudine treatment failure in preventing fatal outcome of de novo severe acute hepatitis B in patients with haematological diseases. Journal of Hepatology, 2001, 35, 823-826.	1.8	20
43	Molecular epidemiology of TT virus in Italy and phylogenesis of viral isolates from subjects at different risk for parenteral exposure. Journal of Medical Virology, 2001, 63, 76-84.	2.5	16
44	Nonneutralizing Human Antibody Fragments against Hepatitis C Virus E2 Glycoprotein Modulate Neutralization of Binding Activity of Human Recombinant Fabs. Virology, 2001, 288, 29-35.	1.1	38
45	Mapping B-Cell Epitopes of Hepatitis C Virus E2 Glycoprotein Using Human Monoclonal Antibodies from Phage Display Libraries. Journal of Virology, 2001, 75, 9986-9990.	1.5	45
46	Transmission of Hepatitis C Virus in a Gynecological Surgery Setting. Journal of Clinical Microbiology, 2001, 39, 2860-2863.	1.8	57
47	Molecular epidemiology of TT virus in Italy and phylogenesis of viral isolates from subjects at different risk for parenteral exposure. Journal of Medical Virology, 2001, 63, 76-84.	2.5	4
48	Dominant Role of Host Selective Pressure in Driving Hepatitis C Virus Evolution in Perinatal Infection. Journal of Virology, 2000, 74, 4327-4334.	1.5	56
49	Epitope mapping of human antibody response against HCV/E2 glycoproteinby generation of monoclonal recombinant fabs. Journal of Hepatology, 2000, 32, 46.	1.8	0
50	Molecular Epidemiology of an Outbreak of Fulminant Hepatitis B. Journal of Clinical Microbiology, 2000, 38, 2975-2981.	1.8	40
51	Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and Thl-like response in chronic hepatitis C. Liver International, 1999, 19, 212-219.	1.9	69
52	Prophylaxis of Hepatitis C with Intramuscular Immunoglobulin. BioDrugs, 1999, 12, 291-300.	2.2	5
53	Dynamics of hepatitis C viremia after plasma exchange. Journal of Hepatology, 1999, 31, 389-393.	1.8	25
54	Exacerbation of chronic hepatitis D during interferon alpha administration. Italian Journal of Gastroenterology and Hepatology, 1999, 31, 66-9.	0.5	3

#	Article	IF	CITATIONS
55	Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant fab fragments. Hepatology, 1998, 28, 810-814.	3.6	51
56	TOFE human-B-cell-line-based adsorption-inhibition assay to detect HCV neutralizing antibodies. Research in Virology, 1998, 149, 331-333.	0.7	0
57	Sustained alanineaminotransferase (ALT) normalization regardless of virus eradication is associated with long-lasting histologic improvement in chronic hepatitis C (CHC) patients treated with interferon-1± (IFN). Gastroenterology, 1998, 114, A1217.	0.6	0
58	Sexual Transmission of Hepatitis C Virus and Prevention with Intramuscular Immunoglobulin. AIDS Patient Care and STDs, 1998, 12, 611-618.	1.1	3
59	Evolution of Hypervariable Region 1 of Hepatitis C Virus in Primary Infection. Journal of Virology, 1998, 72, 6271-6276.	1.5	80
60	Characterization of hepatitis C virus genotypes in an hemodialysis unit in Paysandú, Uruguay. Revista Argentina De Microbiologia, 1998, 30, 190-4.	0.4	1
61	Dynamic Features of Human Immunodeficiency Virus Type 1 (HIVâ€1) Viremia: Kinetics of Cellâ€Free HIVâ€1 RNA after Therapeutic Plasma Exchange. Journal of Infectious Diseases, 1997, 176, 801-804.	1.9	10
62	Quantitation of hepatitis C virus RNA production in two human bone marrow-derived B-cell lines infected in vitro. Research in Virology, 1997, 148, 147-151.	0.7	17
63	Human monoclonal recombinant Fabs specific for HCV antigens obtained by repertoire cloning in phage display combinatorial vectors. Research in Virology, 1997, 148, 165-169.	0.7	29
64	Dynamics of viral quasispecies in hepatitis C virus infection. Research in Virology, 1997, 148, 171-176.	0.7	1
65	Hepatitis C virus infection of a Vero cell clone displaying efficient virus-cell binding. Research in Virology, 1997, 148, 181-186.	0.7	12
66	Molecular characterization and dynamics of hepatitis C virus replication in human fetal hepatocytes infected in vitro Hepatology, 1997, 26, 1328-1337.	3.6	4
67	Quantitative liver parameters of HCV infection: relation to HCV genotypes, viremia and response to interferon treatment. Journal of Hepatology, 1997, 26, 779-786.	1.8	27
68	Clinical implications of GBV-C/HGV infection in patients with "HCV-related―chronic hepatitis. Journal of Hepatology, 1997, 26, 1165-1172.	1.8	46
69	Quantitative analysis of hepatitis C virus activity in vivo in different groups of untreated patients. Archives of Virology, 1997, 142, 465-472.	0.9	10
70	Molecular characterization and dynamics of hepatitis C virus replication in human fetal hepatocytes infectedin vitro. Hepatology, 1997, 26, 1328-1337.	3.6	84
71	A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology, 1997, 26, 1621-1625.	3.6	172
72	Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. Archives of Internal Medicine, 1997, 157, 1537-44.	4.3	22

#	Article	IF	CITATIONS
73	Histological changes but not virus eradication reflect biochemical improvement in chronic hepatitis C patients showing a long-term response to interferon alpha therapy. Italian Journal of Gastroenterology and Hepatology, 1997, 29, 31-7.	0.5	3
74	Low hepatitis C viremia levels in patients with anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis. Journal of Hepatology, 1996, 25, 433-438.	1.8	23
75	Clinical use of quantitative molecular methods in studying human immunodeficiency virus type 1 infection. Clinical Microbiology Reviews, 1996, 9, 135-147.	5.7	31
76	Hepatitis C virus infection and mixed cryoglobulinaemia: assessment of HCV RNA copy numbers in supernatant, cryoprecipitate and non-liver cells. Journal of Viral Hepatitis, 1996, 3, 285-292.	1.0	15
77	Differential humoral immune response against hepatitis C virus antigenic synthetic peptides in infected patients with and without mixed cryoglobulinaemia. Clinical and Experimental Immunology, 1996, 105, 59-64.	1.1	14
78	Clinical use of quantitative molecular methods in studying human immunodeficiency virus type 1 infection Clinical Microbiology Reviews, 1996, 9, 135-147.	5.7	0
79	Adenoma-Carcinoma Sequence of Colorectum. Diagnostic Molecular Pathology, 1995, 4, 198-202.	2.1	12
80	Quantitative molecular methods in virology. Archives of Virology, 1995, 140, 1523-1539.	0.9	54
81	Viral load in samples from hepatitis C virus (HCV)-infected patients with various clinical conditions. Research in Virology, 1995, 146, 279-284.	0.7	9
82	Hepatitis B virus precore mutants in HBeAg carriers with chronic hepatitis treated with interferon. Journal of Viral Hepatitis, 1995, 2, 251-256.	1.0	17
83	Quantitative molecular monitoring of human immunodeficiency virus type 1 activity during therapy with specific antiretroviral compounds. Journal of Clinical Microbiology, 1995, 33, 16-23.	1.8	41
84	Chronic liver disease and active hepatitis C virus infection in patients with antibodies to this virus Journal of Clinical Pathology, 1994, 47, 148-151.	1.0	7
85	Competitive polymerase chain reaction and analysis of viral activity at the molecular level. Genetic Analysis, Techniques and Applications, 1994, 11, 1-6.	1.5	24
86	Presence of hepatitis C virus (HCV) genomic RNA and viral replicative intermediates in bone marrow and peripheral blood mononuclear cells from HCV-infected patients. Vaccine Journal, 1994, 1, 160-163.	2.6	37
87	Quantitation of hepatitis C virus genome molecules in plasma samples. Journal of Clinical Microbiology, 1994, 32, 1939-1944.	1.8	59
88	Dynamics of molecular parameters of human immunodeficiency virus type 1 activity in vivo. Journal of Virology, 1994, 68, 2495-2502.	1.5	70
89	Trans-Activation of Epidermal Growth Factor Receptor Gene by the Hepatitis B Virus X-Gene Product. Virology, 1993, 196, 878-882.	1.1	68
90	Clearance of HIV-1 viraemia after seroconversion. Lancet, The, 1993, 341, 315-316.	6.3	21

#	Article	IF	CITATIONS
91	Quantitative PCR and RT-PCR in virology Genome Research, 1993, 2, 191-196.	2.4	148
92	Direct detection of HBV preC mutants in heterogeneous viral populations by a modified DNA sequencing method. Research in Virology, 1993, 144, 303-306.	0.7	6
93	Hepatitis B virus preC mutants in human hepatocellular carcinoma tissues. Research in Virology, 1993, 144, 297-301.	0.7	17
94	Transmission of Hepatitis C via Blood Splash into Conjunctiva. Scandinavian Journal of Infectious Diseases, 1993, 25, 270-271.	1.5	145
95	Sequence analysis of the hepatitis B virus pre-C region in hepatocellular carcinoma [HCC] and nontumoral liver tissues from HCC patients. Virology, 1992, 188, 890-895.	1.1	29
96	Human immunodeficiency virus type 1 and hepatitis B virus transcription in peripheral blood lymphocytes from co-infected subjects. Archives of Virology, 1992, 126, 1-9.	0.9	18
97	Lack of detectable human T-cell lymphotropic virus type I sequences in samples from multiple sclerosis patients. Journal of Medical Virology, 1992, 36, 155-161.	2.5	9
98	Absolute quantitation of viremia in human immunodeficiency virus infection by competitive reverse transcription and polymerase chain reaction. Journal of Clinical Microbiology, 1992, 30, 1752-1757.	1.8	185
99	Molecular profile of human immunodeficiency virus type 1 infection in symptomless patients and in patients with AIDS. Journal of Virology, 1992, 66, 7328-7335.	1.5	133
100	PCR analysis of HBV infected sera: relationship between expression of pre-S antigens and viral replication. Archives of Virology Supplementum, 1992, 4, 113-115.	3.0	1
101	A single-step DNA extraction procedure for the detection of serum hepatitis B virus sequences by the polymerase chain reaction. Journal of Virological Methods, 1991, 32, 245-253.	1.0	25
102	Detection of human immunodeficiency virus type 1 transcripts in peripheral blood lymphocytes by the polymerase chain reaction. Journal of Virological Methods, 1991, 32, 31-39.	1.0	24
103	Detection of human immunodeficiency virus type 1 genomic RNA in plasma samples by reverse-transcription polymerase chain reaction. Journal of Medical Virology, 1991, 34, 89-95.	2.5	49
104	Levels of Pre-S antigens and HBV DNA in sera from high and low viremic HBV carriers. Journal of Medical Virology, 1991, 35, 273-282.	2.5	8
105	Growth-factor independence of a new differentiated hepatitis B virus DNA-negative human hepatoma cell line. Hepatology, 1990, 11, 1024-1032.	3.6	8
106	Detection of hepatitis B virus DNA in serum using synthetic non-radioactive oligonucleotides Journal of Clinical Pathology, 1989, 42, 1206-1210.	1.0	8
107	Antibody response to individual cytomegalovirus structural proteins in different groups of subjects. European Journal of Clinical Microbiology and Infectious Diseases, 1987, 6, 207-210.	1.3	10
108	Detection of HBV infectivity by spot hybridization in HBeAg-Negative chronic carriers: HBV DNA in sera from asymptomatic and symptomatic subjects. Journal of Medical Virology, 1987, 21, 15-23.	2.5	26

#	Article	IF	CITATIONS
109	Human growth hormone induced modulation of hepatitis B virus (HBV) gene expression. Developments in Biological Standardization, 1987, 66, 409-16.	0.2	0
110	Comparative effects of α, β and γ human interferons on a HBsAg-producing human hepatoma cell line. Research in Clinic and Laboratory, 1986, 16, 457-462.	0.3	1
111	Characterization of growth parameters of a human hepatoma cell line cultured under serum-free conditions. Research in Clinic and Laboratory, 1985, 15, 151-158.	0.3	1